Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
February 10, 2022 4:05 PM EST2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million
2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million
Strong Dojolvi® launch continues with approximately 270 patients on reimbursed commercial therapy in the United States as of the end of 2021
Year-end 2021 cash balance of approximately $1.0 billion
NOVATO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and... More
